WS #9285

The Israel-Iran conflict has escalated sharply with new missile and drone strikes, including an Israeli attack on the Karun Petrochemical Company in Iran and Iranian strikes on Israeli targets. Despite Trump's ceasefire call, the situation is worsening, with oil prices rising 4% and the Strait of Hormuz traffic normalization probability falling to 31%. This is a clear escalation from the prior window's 'stable' narrative. On the corporate side, Incyte's $1.25B acquisition of Vega Therapeutics is a significant M&A signal for biotech. Tango Therapeutics reported a 92% objective response rate in pancreatic cancer, a major positive for TNGX. Campbell's reported mixed Q3 results (EPS beat, revenue miss) and affirmed guidance. Ciena announced a $2B convertible note offering. Saudi Arabia cut OSPs for July, signaling weakening demand. The macro picture shows inflation reaccelerating (CPI 3.8%, core PCE 4.3%), European stocks falling on oil surge, and gold selling off. The dominant narrative is ESCALATING: the Middle East conflict is intensifying, offsetting any ceasefire hopes from the prior window.